

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/305223911>

# Induced Pluripotent Stem Cells (IPSCs) Line Derived from H103—Orals Squamous Cell Carcinoma (OSCC) Cells

Conference Paper · May 2016

CITATIONS

0

READS

69

1 author:



[Nalini Devi Verusingam](#)

Universiti Tunku Abdul Rahman

9 PUBLICATIONS 18 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Cancer derived induced pluripotent stem cells; Cell based gene therapy [View project](#)



Elucidation of CircularRNA(circRNA) in Osimertinib (Third Generation EGFR-TKI) Resistant NSCLC [View project](#)

Nalini Devi Verusingam<sup>1,2</sup>, Swee Keong Yeap<sup>3</sup>, Ian Charles Paterson<sup>4</sup>, Soon Keng Cheong<sup>1,2</sup>, Han Kiat Ong<sup>1</sup>

<sup>1</sup> Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, 43000 Kajang, Malaysia.

<sup>2</sup> PPUKM-MAKNA Cancer Centre, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur.

<sup>3</sup>Institute of Bioscience, Universiti Putra Malaysia, 43400 Serdang, Malaysia.

<sup>4</sup> Faculty of Dentistry Dean's Office, Faculty of Dentistry, University of Malaya, 50603 Kuala Lumpur, Malaysia.

\*Corresponding Author: onghk@utar.edu.my

## INTRODUCTION


Cancer Cells can be reprogrammed into induced pluripotent stem cells (IPSCs) by forced expressions of pluripotency vectors (oct4, sox2, klf4 and c-Myc). Previous studies have shown the generated pluripotent stem cells from cancer cells achieved pluripotency capacity, but retain the genetic aberrations [1,2]. These properties facilitate cancer oncogenesis development study not achievable with current cancer models. To date, reprogramming of OSCC remained unexplored [3]. Hence, the urge to understand the cancer pathogenesis, prevention and treatment of OSCC leads to the proposed application of reprogramming technology. Derived OSCC-IPSCs may provide enormous application as a suitable oncogenesis model as well as cancer stem cell-targeted drug screening and toxicity testing.

## OBJECTIVES


1. To reprogramme Oral Squamous Carcinoma Cell Lines into iPSCs derivatives.
2. To characterize its pluripotency properties for further downstream analysis.

## METHODOLOGY

### Step 1: Culturing of HI03 Cells



### Step 2: Generation of iPSCs




Yamanaka's Cocktail (Oct4, Sox2, Klf4 and c-Myc)




Integrating Viral Vector System used:  
Retroviral-OSKM

### Step 3: Characterization of iPSCs Colonies




Characterization of morphology, pluripotency markers, embryoid bodies formation and directed differentiation capacity.


### Step 4: Expand iPSCs Colonies




## RESULTS




**Figure 1: Reprogrammed HI03 OSCC-Grade I.** (A) Morphology of HI03 parental cancer cells, magnification:10x. (B) Representative image of an established HI03-IPSC cell colonies at Passage 15 on MEF feeder layer. Distinct morphologies observed between parental cancer cells and the iPSCs derivatives. Red arrow indicates the clear borders of derived HI03-IPSCs, magnification:4x.




**Figure 2: Expression of Pluripotent Markers in HI03-IPSC.** (A-D) HI03-IPSCs colonies expressed markers common to pluripotent cells including OCT4, SOX2, NANOG, and TRA-1-60. Magnification: 10x



**Figure 3: Embryoid Bodies (EBs) formation.** Representative images of (A) parental HI03-EB cells and (B) HI03-IPSC-EB cultured in suspension for 8days. EBs from parental HI03 was lack of compact structure and round borders unlike in HI03-IPSC. Nikon inverted microscope, original magnification: 10x.



**Figure 4: Immunofluorescence (IF) staining of parental HI03-EB and HI03-IPSCs-EB.** (A&B) Representative images of parental HI03-EB cells and HI03-IPSCs-EB stained for embryoid bodies mesoderm marker (BRACHYURY). EB mesoderm expression was not detected in parental HI03 but expressed in HI03-IPSCs derived embryoid bodies. Nikon inverted microscope, original magnification: 10x.



**Figure 5: Differentiations into Osteocytes and Adipocytes.** (A) Control parental HI03 cells showing negative for the Alizarin red staining (B) HI03-IPSCs cells showing positive for the Alizarin red staining indicating. Calcium deposits indicated by their red colour. (Red arrow) (C) Negative staining for Oil-O-Red in control parental HI03 cells. (D) Adipogenesis induced lipid droplets observed in red colour after Oil-O-Red staining. (Red arrow) indicates the tiny lipid droplets. Nikon inverted microscope, original magnification: (A & B) 10x, (C & D) 40x.

## DISCUSSION

- **IPSC** cells were **successfully** established from parental HI03 (OSCC) cancer cell line via retrovirus OSKM-based expression system.
- **Stable HI03-IPSCs** exhibit **Embryonic Stem Cells (ESCs)** morphology and can be passaged *in-vitro* above passage 20 without change of properties indicative of self renewal (**Fig 1**).
- Presence of **pluripotency** expressions were **confirmed** by means of immunofluorescence staining in HI03-IPSCs (**Fig 2**).
- **HI03-IPSCs** formed 'embryoid bodies' with **compact structure** and **round borders**. Presence of **mesoderm marker (BRACHYURY)** in EB was **confirmed** by means of immunofluorescence staining (**Fig 3 & Fig 4**).
- **HI03-IPSCs** derived from HI03 (OSCC) cancer cell line which originated from ectoderm-endoderm lineage, **was successfully** shown to posse **cross lineage differentiation capability** into **adipocytes** and **osteocytes** stained positive for **Oil-O-Red** and **Alizarin Red** respectively (**Fig 5**).
- In summary, **reprogramming** was **successful** in **HI03** cell line phenotypically exhibit **ESCs** like characteristics based on cell morphology, pluripotency signals and differentiation capacity.
- Derived HI03-IPSCs potentially used to develop **patient specific disease model** to assess **its cancer pathogenesis** in future studies.

### References:

1. Kim, J. and Zaret, K. S., 2015. Reprogramming of human cancer cells to pluripotency for models of cancer progression. *The EMBO Journal*, 34, pp.739-747.
2. Lee, D. F., et al., 2015. Modeling Familial Cancer with Induced Pluripotent Stem Cells. *Cell*, 161, pp.240-254.
3. Lang, J. Y., Shi, Y. and Chin, Y.E. 2013. Reprogramming cancer cells: back to the future. *Oncogene*, 2:32.

### Acknowledgement:

The authors would like to extend their deepest gratitude to UTARRF (6200/A11) for funding this research.